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ABSTRACT      During the past three decades, human in vitro fertilization (IVF) has changed from disdained technique to one which consti-
tutes a respected branch of modern medicine. Concerns connected with human in vitro fertilization have not materialized. On the other hand, 
in vitro fertilization has demonstrated benefits in unexpected areas. When combined with techniques of molecular genetics such as preim-
plantation genetic diagnostics, it can prevent the occurrence of hereditary diseases. In vitro fertilization is greatly needed even in developing 
countries, despite the fact that the Third World is heavily confronted with the impacts of population explosion.
At present, many new and promising biotechnologies are fighting strong opposition from the public. The history of human IVF recurs. Even 
hypothetical risks are emphasized, and many future benefits are not recognized or cannot be recognized at the present state of knowledge.
The significant progress of human IVF provides us with a lesson for the evaluation of impending biotechnologies. The setting of rigid limits or 
imposing bans on new biotechnologies can significantly restrict the future prosperity of mankind.
ABSTRAKT      Za tři desetiletí se technika in vitro oplození proměnila z oboru, v který věřil jen málokdo, na techniku, která je pevnou sou-
částí moderní medicíny. Obavy, které s ní byly spojovány, se nenaplnily. Naopak, in vitro oplození našlo uplatnění i tam, kde to nikdo nepřed-
pokládal. V kombinaci s předimplantační genetickou diagnostikou se využívá jako prevence dědičných onemocnění. Potřeba oplození in vitro 
se ukázala i v zemích třetího světa, které se potýkají s důsledky populační exploze.
V současnosti se rozvíjejí nové biotechnologie, které narážejí na odpor veřejnosti. Historie se opakuje. Jsou zdůrazňovány především jejich 
možná i ryze hypotetická rizika a mnohé jejich budoucí přínosy nejsou a za současného stavu poznání ani nemohou být předvídány.
Rozvoj in vitro oplození nabízí lekci pro hodnocení nastupujících biotechnologií. Jejich výrazné omezení nebo dokonce zákaz by zjevně zna-
menaly pro budoucnost lidstva závažná omezení.
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The awarding of the Nobel Prize for Physiology and Medicine 
in 2010 to Robert G. Edwards “for the development of in vitro 
fertilization” (Nobel Assembly at Karolinska Institutet, 2010) 
confirmed the magnitude of this medical technique for our 
present world. However, the first news about a child born af-
ter in vitro fertilization (IVF) (Steptoe – Edwards, 1978) met 
both with euphoria and reluctance. Even the initial research 
which opened the way to this breakthrough was opposed by 
fierce discussions (Johnson et al., 2010).
The basics of human IVF were established in 1969 (Edwards 
et al., 1969). However, further progress in this area met with 
difficult early days of human in Vitro 
fertiliZation
strong resistance even within the scientific community. Fau-
ser and Edwards (2005) stated that “at one stage, Edwards 
had only three or four supporters at Cambridge”. According 
to Martin Johnson of Cambridge University, one of Edward’s 
first graduate students, there was a “strange atmosphere” in 
the 1960s and 1970s with regard to human in vitro fertiliza-
tion (Abbott 2010). Even Cambridge Nobel laureates Max 
Perutz and James Watson did not hesitate to express their opi-
nion that it is “irresponsible to interfere with the beginning of 
life” (Abbott, 2010).
In 1971 the British Medical Research Council (MRC) refu-
sed to approve a grant to Edwards and Steptoe for research 
on human in vitro fertilization. The MRC rationalized this 
by stating that the treatment of human infertility has a “low 
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priority compared with population control”. The MRC perce-
ived research on human fertilization as “purely experimental 
rather than potential treatment” (Johnson et al., 2010). The 
negative decision in 1971 influenced the attitude of the MRC 
to human IVF for the next eight years. Only after the birth of 
two healthy babies from IVF did the MRC swiftly convert to 
enthusiastic support of human in vitro fertilization.  
More than four million children were born over more than 
three decades using IVF. During this time it was clearly de-
monstrated that many fears and doubts were unfounded. Fe-
ars of low biological safety of IVF (Johnson et al., 2010) or 
fear of profound social changes induced by the introduction 
of IVF (Baslington, 1996; Hanmer, 1987; Mies, 1985) did not 
materialize. The attitudes of religious communities and chur-
ches differed substantially. There is still a wide spectrum of 
attitudes – strict rejection by the Catholic Church, tolerance 
in Protestant, Anglican and other Christian denominations, 
and the positive attitude of Judaism and Islam when IVF is 
used for conception of a child by husband and wife (Schenker, 
2005).
Discussion on the bioethical aspects of IVF and other techni-
ques of so-called assisted reproduction (AR) continues despi-
te the fact that these techniques are widely accepted as an in-
tegral part of modern medicine. Critics focus not on assisted 
reproduction per se but rather on some special aspects of AR, 
and especially on individual controversial cases. 
Pregnancy of postmenopausal women performed by transfer 
of embryos conceived in vitro from donated oocytes (Borini et 
al., 1995) is often strongly criticized. The advanced age of the 
mother, even over seventy, does not guarantee that the mother 
will be able to care for the child for the necessary period. For 
this reason, IVF cannot be used for the purpose of pregnancy 
in postmenopausal women in some countries, and these wo-
men are denied treatment using assisted reproduction. Such 
a decision raises the question of the ethical acceptance of such 
denials and also raises the question if there is a reason to deny 
assisted reproduction to other people with reduced ability to 
fulfill parental duties, e. g., to drug addicts or alcoholics.
A very complicated situation can occur after donation of oo-
cytes, sperm or embryos (Van Voorhis et al., 1999; Murray – 
Golombok, 2000; Frith, 2001) because there are several people 
who are bound to the child by strong bonds – emotional, legal 
or biological. Anonymous donation of gametes or embryos 
prevents a conceived child from knowing about his biological 
parents. However, the introduction of an onymous donation 
of gametes or embryos has been accompanied by a sharp dec-
line in the number of donors (Janssens et al., 2006).
A very complicated situation could arise concerning deciding 
about the fate of cryopreserved embryos when the opinions 
of the biological parents differ. One parent wants to implant 
embryos and conceive a baby, but this is strongly rejected by 
the other parent. This issue is difficult to decide because one 
of the fundamental principles is that the fate of cryopreser-
Bioethical questions of iVf
ved embryos must be agreed upon by both biological parents 
(Smajdor, 2007; Sozou et al., 2010). Another significant bio-
ethical and even legal question accompanies the use of sur-
rogate mothers for the development of embryos of foreign 
parents (van Niekerk – van Zyl, 1995; Poster, 1989).
These discussions became more heated after every really con-
troversial case connected with IVF or assisted reproduction, 
e.g., after intentional transfer of a high number of embryos 
with the intention of establishing a multiple pregnancy (Ory, 
2010; Rosenthal, 2010). On January 26, 2009, Nadya Suleman 
gave birth to octuplets and became famous. Over the course 
of one month Ms. Suleman became a subject of outrage and 
outrageous representations over conception by in vitro fertili-
zation and of the details of her personal life. This thirty-years-
old single woman chose to have in vitro fertilization since she 
already had six children from in vitro fertilization with other 
men.
Many expected negative effects of in vitro fertilization have 
not occurred. Just the opposite was the case. In vitro fertiliza-
tion served as the starting platform for other techniques of as-
sisted reproduction which alleviated many complicated cases 
of human infertility. Cryoconservation of embryos (Trounson 
– Moor, 1994) is one such complementary technique of assis-
ted reproduction. It enables the storage of surplus embryos 
conceived by in vitro fertilization of multiple oocytes retrie-
ved from a patient after hormonal stimulation. Cryopreser-
ved embryos can be used by their biological parents for con-
ceiving other children without another hormonal treatment 
of the mother and without the procedure of oocyte retrieval.
Intracytoplasmatic sperm injection (ICSI) allows the fertiliza-
tion of oocytes by sperm which are for various reasons unable 
to penetrate the oocyte (Palermo et al., 1993). ICSI enables 
even fertilization of human oocytes with earlier developmen-
tal stages of male gametes, e.g., elongated spermatids or roun-
ded spermatids (Fishel et al., 1997). This opened the way to 
fatherhood to men with seriously damaged spermatogenesis.
In vitro fertilization is employed even in areas which were 
quite unexpected in the early days of development of this 
technique. This is the case of preimplantation genetic diagno-
sis (PGD), which involves IVF even in fully fertile couples 
(Handyside et al., 1990). PGD is used for the prevention of he-
ritable diseases. IVF is performed in couples which encounter 
the possibility that their child will be born with a heritable 
disease such as cystic fibrosis, Duchenne muscular dystrophy 
or hemophilia. One or two cells are removed from embryos 
cultured in vitro and the DNA of these cells is subjected to 
genetic analysis focusing on selected mutations. Only embry-
os without genetic defects are transferred to the mother, and 
therefore it is sure, that the newborn baby will not suffer from 
a heritable disease. Before PGD, the only options for the pre-
vention of heritable diseases were prenatal genetic diagnosis 
and artificial abortion.
new Benefits of assisted reproduction
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PGD is really a breakthrough in the prevention of heritable 
diseases. However, even PGD brings its own controversies. 
The majority of the public perceives deafness as a disability 
which should be prevented. These people might agree with 
PGD which prevents the birth of a child with heritable deaf-
ness. However, a small part of the deaf community prefers the 
birth of a deaf child. These so called “capital-D-Deaf ” do not 
perceive deafness as a disability but rather as a culture which 
they want to share with their children (Davis, 1997; Lane, 
2002). 
In vitro fertilization is quite paradoxically a technique which 
can alleviate many problems of inhabitants of the Third World. 
Despite the ongoing population explosion, infertility is a very 
serious problem in developing countries. There are about 80 
million infertile people in the world, and the majority of them 
live in the Third World. These people have no access to regu-
lar, basic health care. Access to therapy for infertility is even 
much more limited. When compared to the Western World, 
infertility has much stronger negative consequences in deve-
loping countries. It is often accompanied by social isolation, 
economic deprivation and even brutal violence against infer-
tile women.
The main reasons for female infertility in developing coun-
tries are sexually transmitted diseases, unsafe abortions and 
postpartum infections. Prevention can bring significant im-
provement of this sorry condition. However, in many infer-
tile women only assisted reproduction can bring help. This 
treatment is affordable for only a very limited number of we-
althy people in the Third World and is inaccessible for most 
of those who need it. There is a huge effort to develop simple 
and cost-effective techniques of assisted reproduction which 
could be applied in Third World countries for the treatment of 
infertility and for a solution to the complex of social problems 
emanating from infertility (Ombelet, 2007).
iVf for the third world
Approximately at the time when the Nobel Assembly an-
nounced the award of the Nobel prize to Robert Edwards, the 
American biotechnological firm Geron Corporation began 
the Phase I of a clinical trial for treatment of patients para-
lyzed after spinal cord injury with cells derived from human 
embryonic stem cells (Geron Corporation, 2010).
The beginnings of this type of cell therapy were initiated by 
Robert Edwards and his coworkers (Steptoe et al., 1971). 
A solid basis for this therapy was found in 1998 after establis-
hment of the first lines of pluripotent stem cells obtained from 
in vitro culture of human blastocysts (Thomson et al., 1998). 
These cells, called human embryonic stem cells, have unlimi-
ted ability to divide. After culture under specific in vitro con-
emBryonic stem cells and other new 
Biotechnologies
ditions, the embryonic stem cells differentiate into every type 
of cell in the human body including gametes. The potential of 
these cells for the treatment of injuries, degenerative diseases 
and many other pathological states is immense. The objective 
of the Phase I clinical trial performed by Geron Corporation 
and the Shepherd Center in Atlanta was to heal the myelin 
sheet of damaged axons of the injured spinal cord and to reco-
ver the mobility of patients (Geron Corporation, 2010). 
Treatment with cells derived from embryonic stem cells is 
based on the research of Robert Edwards, because embryonic 
stem cells are derived from cells taken from surplus human 
embryos produced for infertility treatment using in vitro fer-
tilization. Treatment with human embryonic stem cells and in 
vitro fertilization share strong opposition from a certain part 
of the public.
The history of the controversial acceptance of human in vitro 
fertilization repeats itself with human embryonic stem cells. 
There are attempts to stop research on embryonic stem cells. 
These attempts can substantially delay or even prevent the 
advance of new treatments which can cure many people or 
even save their lives (Moreno et al., 2010).
Many other promising biotechnologies are battling similar 
obstacles. For example, there are attempts to create micro-
organisms with a minimal synthetic genome (Lartigue et 
al., 2009). These microorganisms could be used in the near 
or distant future for inexpensive and effective production of 
drugs, vaccines, or for cost-effective production of “green” 
energy. Opponents of so-called synthetic biology prefer to 
emphasize the potential risks and demand substantial limita-
tion both of research and of the exploitation of the products 
of synthetic biology (Calvert, 2008).
Genetically modified crops also face very strong opposition 
(Gaskell et al., 2000; Trewavas – Leaver, 2001) although these 
crops could solve the problem of world famine and malnu-
trition in the Third World. Genetically modified organisms 
could be also used for the production of drugs, vaccines, eli-
mination of toxic pollutants from soil, etc.
Based on experience from more than three decades of exploi-
tation of human IVF, it is clear that humankind is able to con-
trol the development of new biotechnologies in such a man-
ner that it can use their benefits to advantage and eliminate 
their potential risks. People are able to solve very complicated 
bioethical problems which accompany the use of assisted re-
production.  
It is reasonable to assume that new emerging biotechnologies 
which face the opposition of the public have the same poten-
tial. Some of their benefits cannot even be anticipated. On the 
other hand, their potential risks are probably exaggerated.
Opposition to emerging biotechnologies is concentrated in 
certain parts of world. The rejection of human embryonic 
stem cells seems to be much stronger in the United States 
than in Europe. The opposition to genetically modified crops 
conclusions
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is much stronger in the European Union than in any other 
part of the world. This indicates that the roots of this opposi-
tion do not stem from a factual evaluation of biological pro-
cesses, but rather from political, cultural, religious and social 
reasons. Objections to emerging biotechnologies are often 
based on emotional grounds. This does not imply that such 
emotion-based opposition is weak. Rather, the opposite is the 
case. Draconic bans and strong restrictions imposed on new 
emerging biotechnologies do not prevent disasters, as these 
disasters are easily avoidable, or they do not represent a real 
threat at all. Such bans and restrictions can significantly con-
strain possibilities of humankind to solve important future 
challenges.
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